Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: A prospective study

Lancet

Volumn 358, Issue 9299, 2001, Pages 2113-2117

  Zoccali, Carmine ^e   Bode Böger, Stefanie M ^a   Mallamaci, Francesca ^e   Benedetto, Frank Antonio ^e   Tripepi, Giovanni ^e   Malatino, Lorenzo Salvatore ^d   Cataliotti, Alessandro ^d   Bellanuova, Ignazio ^d   Fermo, Isabella ^c   Frölich, Jürgen C ^a   Böger, Rainer H ^b   Enia, Giuseppe ^f   Parlongo, Saverio ^f   Cutrupi, Sebastiano ^f   Tripepi, Rocco ^f   Panuccio, Vincenzo ^f   Marino, Carmela ^f   Rapisarda, Francesco ^d   Fatuzzo, Pasquale ^d   Bonanno, Grazia ^d   Seminara, Giuseppe ^d   Stancanelli, Benedetta ^d   Candela, Vincenzo ^g   Labate, Carlo ^g   Tassone, Filippo ^h   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e CNR Centre of Clinical Physiology and Renal Unit   (France)

^f CNR   (Italy)

^g Servizio Dialisi di Melito Porto Salvo   (Italy)

^h Servizio di Cardiologia Ospedale 'E Morelli'   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ARGININE; CHOLESTEROL; FIBRINOGEN; N(G),N(G) DIMETHYLARGININE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; AMINO ACID BLOOD LEVEL; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HAZARD ASSESSMENT; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY;

EID: 0035936406     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(01)07217-8     Document Type: Article

References (29)

1. Cardiovascular risk in uraemic patients: Is it fully explained by classical risk factors?
2. Controlling the epidemic of cardiovascular disease in chronic renal disease: Where do we start?
3. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure
4. Asymmetric dimethylarginine: A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia
5. G-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor, in dialysis patients
6. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: Relationship to treatment method and atherosclerotic disease
7. Endogenous nitric oxide synthase inhibitor: A novel marker of atherosclerosis
8. Prediction of left ventricular geometry by clinic, pre-dialysis and 24-h ambulatory BP monitoring in hemodialysis patients
9. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease
10. The clinical pharmacology of L-arginine
11. Physiology and biochemistry of endothelial function in children with chronic renal failure
12. Hemodialysis and L-arginine, but not D-arginine, correct renal failure-associated endothelial dysfunction
13. Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure
14. Response of cerebral blood vessels to an endogenous inhibitor of nitric oxide synthase
15. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease
16. G-dimethylarginine dimethylaminohydrolase, from rat kidney
17. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension
18. Novel mechanism for endothelial dysfunction. Dysregulation of dimethylarginine dimethylaminohydrolase
19. Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase
20. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia
21. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells
22. Increase of an endogenous inhibitor of nitric oxide synthesis in serum of high cholesterol fed rabbits
23. Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolemic rabbits
24. Antiatherosclerotic effects of L-arginine in the hypercholesterolemic rabbit
25. Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: Comparison with lovastatin
26. Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolaemic patients by L-arginine
27. Restoring vascular NO formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease
28. Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans